Plasma separation and sample metering device and kits and methods of use related thereto

Patent metadata

Field	Value
Publication number	US-11850583-B2
Application number	US-202017617881-A
Country	US
Kind code	B2
Filing date	Jun 5, 2020
Priority date	Jun 12, 2019
Publication date	Dec 26, 2023
Grant date	Dec 26, 2023

Abstract

Devices, kits, and methods separating and metering a plasma sample from a patient's liquid test sample.

First claim

What is claimed is:

1. A method of separating and metering a plasma sample from a patient's liquid test sample for use within at least one diagnostic assay, the method comprising the steps of:
collecting a patient's liquid test sample into a sample device, the sample device comprising:
a top portion, the top portion comprising a first end, a second end, a top side, a bottom side, and a sample channel disposed between the top side and bottom side and having a first opening at the second end for collecting the patient's liquid test sample, the sample channel extending longitudinally from the second end to the first end of the top portion, wherein the first end has a second opening;
a bottom portion, the bottom portion comprising a first end, a second end, a top side, and a bottom side, wherein the bottom portion is secured to the top portion;
at least one red blood cell capture membrane, the at least one red blood cell capture membrane comprising a first end and a second end, wherein the second end of the red blood cell capture membrane is in substantially direct contact with the second opening of the sample channel; and
at least one plasma membrane comprising a first end and a second end, wherein the plasma membrane is configured and structured to hold a specific volume of plasma, wherein the first end of the plasma membrane is in substantially direct contact with the second end of the at least one red blood cell capture membrane, wherein the second end of the plasma membrane extends beyond the first end of the top portion thereby forming an exposed portion of the plasma membrane, wherein the exposed portion of the plasma membrane has a surface area that holds a predetermined volume of plasma, and wherein the exposed portion of the plasma membrane is isolatable from the remainder of the plasma membrane to meter and deliver a predetermined volume of patient plasma for performance of the one or more diagnostic assays;

transferring the patient's liquid test sample from the sample channel into the at least one red blood cell capture membrane such that any red blood cells contained within the patient's liquid test sample are separated and retained within the at least one red blood cell capture membrane, thereby forming a plasma sample;
allowing the plasma sample to flow from the at least one red blood cell capture membrane into the at least one plasma membrane whereby the plasma membrane is filled with the specific volume of plasma such that a predetermined volume of the plasma sample resides and is substantially contained within the exposed portion of the plasma membrane; and
pinching, separating, or cutting off the exposed portion of the plasma membrane to isolate the predetermined volume of the plasma sample for use in at least one diagnostic assay.

2. The method of claim 1 , wherein the patient's liquid test sample comprises a volume of whole blood.

3. The method of claim 2 , wherein the volume of whole blood is from about 10 microliters to about 30 microliters.

4. The method of claim 1 , wherein the diagnostic assay is at least one analyte detection assay for the detection of at least one analyte selected from the group consisting of IgG, IgG CSF, IgG subclasses 1-4, IgA, IgM, Ig/light chain, type kappa, Ig/light chain, type lambda, FLC kappa, FLC lambda, β2-microglobulin, albumin urine, α1-microglobulin urine, α2-microglobulin, β2-microglobulin urine, cystatin C (serum), IgG urine, Ig/light chain, type kappa urine, Ig/light chain, type lambda urine, transferrin urine, α1-acid glycoprotein, C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA), ADNase B, arginosuccinate lyase (ASL), rheumatoid factor (RF), complement C3 protein (C3c), complement C4 protein (C4), high sensitivity CRP, apolipoprotein A-1 (apo A-1), apolipoprotein B (apo B), homocysteine, lipoprotein (a) (Lp(a)), myoglobin, cystatin C, carbohydrate deficient transferrin (CDT), transferrin, IgE, albumin, prealbumin, retinol binding protein (RBP), ferritin, antithrombin III protein (AT-III), plasminogen, haptoglobin, hemopexin, soluble transferrin receptor protein (sTfR), C1 esterase inhibitor, albumin CSF, IgA CSF, IgM CSF, a1-antitrypsin, α2-macroglobulin, apolipoprotein A-II, apolipoprotein E, ceruloplasmin, fibronectin, folate, vitamin B12, vitamin D, brain natriuretic peptide (BNP), creatine kinase-MB (CKMB), high sensitivity troponin I (TNIH), N-terminal pro b-type natriuretic peptide (NT-proBNP), troponin I, microalbumin, 6-acetylmorphine (6-AM), acetaminophen, amphetamines, barbiturates, benzodiazepines, caffeine, cannabinoids, cocaine metabolite(s), ecstasy, ethyl alcohol, methadone, methaqualone, opiates, phencyclidine, propoxyphene, salicylate, tricyclic antidepressants, cyclosporine, mycophenolic acid, sirolimus, tacrolimus, prostate-specific antigen (PSA), human chorionic gonadotropin (hCG), amikacin, carbamazepine, digitoxin, digoxin, gabapentin, gentamicin, lamotrigine, levetiracetam, lidocaine, lithium, methotrexate, N-acetylprocainamide (NAPA), phenobarbital, phenytoin, procainamide, theophylline, tobramycin, topiramate, valproic acid, vancomycin, zonisamide, triidodthyronine (T3), thyroxine (T4), thyroid hormone uptake, thyroid-stimulating hormone (TSH), and combinations thereof.

5. The method of claim 1 , wherein the top portion and bottom portion are constructed from materials selected from the group consisting of low-density polyethylene, high density polyethylene, polystyrene, polyvinylchloride, styrene butadiene, polyacrylics, polyvinyl acetate, and combinations thereof.

6. The method of claim 1 , wherein the at least one red blood cell capture membrane is entirely contained between the top portion and bottom portion of the sample device.

7. The method of claim 1 , wherein the second end of the at least one plasma membrane is located outside of the top portion and bottom portion of the sample device.

8. The method of claim 1 , wherein the at least one red blood cell capture membrane comprises at least one substance selected from the group consisting of concanavalin A, lentil lectin, potato lectin, snowdrop lectin, ricin, peanut agglutinin, jacalin, hairy vetch lectin, wheat germ agglutinin, elderberry lectin, Maackia amurensis hemoagglutinin, Ulex europaeus agglutinin, Aleuria aurantia lectin, anti-human red blood cell antibodies, asymmetric polysulfone membrane(s), and combinations thereof.

9. The method of claim 1 , wherein the at least one plasma membrane is constructed of materials selected from the group consisting of cellulose with binder, cellulose without binder, nitrocellulose, carboxymethylcellulose, glass fiber, synthetic paper, and combinations thereof.

10. The method of claim 1 , wherein at least a portion of the sample channel is at least partially coated with at least one anticoagulant compound.

11. The method of claim 10 , wherein the at least one anticoagulant compound is selected from the group consisting of sodium heparin, lithium heparin, warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, enoxaparin, fondaparinux, ethylenediaminetetraacetic acid (EDTA), and combinations thereof.

12. The method of claim 1 , wherein the patient's liquid test sample is collected by and transferred through the sample device via capillary action.

13. The method of claim 1 , further comprising the step of removing the predetermined volume of plasma from the isolated exposed portion of the plasma membrane by exposing the isolated exposed portion of the plasma membrane to at least one liquid buffer and/or reagent.

14. The method of claim 1 , wherein the step of isolating the exposed portion of the plasma membrane is further defined as severing the exposed

Assignees

• Siemens Healthcare Diagnostics Inc

Inventors

• Kauffmann Aaron
• Ledden David

Classifications

• B01L3/502 Primary

  with fluid transport, e.g. in multi-compartment structures · CPC title

• B01L2200/0605

  Metering of fluids · CPC title

• B01L2400/0406

  capillary forces · CPC title

• B01L3/5023 Primary

  with a sample being transported to, and subsequently stored in an absorbent for analysis · CPC title

• G01N33/491

  by separating the blood components (G01N15/05 takes precedence) · CPC title